Call your doctor before leaving home if you think you’ve been exposed to COVID-19 or have symptoms

Due to the presence of COVID-19 in our community, visitor restrictions are in place for all Duke clinics and hospitals. For your safety and the safety of others, we recommend patients do not bring a visitor to Duke clinics, if at all possible. If a visitor must accompany a patient, only one individual over 12 years of age is allowed. Patients and visitors will be screened for symptoms upon arrival. Individuals with flu-like symptoms are not allowed. View the complete list of Visitor Restrictions.

Effective immediately, Duke Health is prioritizing and rescheduling some non-emergent or non-critical surgeries, procedures, and appointments. Check our COVID-19 (Coronavirus) page for updates.

ArQule: ARQ 531-101 Ph1 ARQ 531 R/R Hematologic Malignancies - Clinical Trial

What is the Purpose of this Study?

We are doing this study to find out what is the best dose of the study drug (ARQ 531) to use in patients with hematologic malignancies.
What is the Condition Being Studied?
Relapsed or Refractory Hematologic Malignancies

Who Can Participate in the Study?

Adults who:
- Have good organ function
- Have a platelet count greater than 50,000/microliters
- Have a creatinine clearance of greater than 60 mL/min
- Have hemoglobin (Hgb) greater than 8.0 g/dL and stable for greater than 1 week

Age Group

What is Involved?

If you choose to join this study, you will:
- Give samples of your blood
- Have assessments of your vital signs
- Give urine samples
- Get the study drug, ARQ 531, taken by mouth for one week

Study Details

Full Title
A Phase 1 Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of ARQ 531 in Selected Subjects with Relapsed or Refractory Hematologic Malignancies
Principal Investigator
Cell Therapy and Hematologic Malignancies Specialist
Protocol Number
IRB: PRO00101876
NCT: NCT03162536
Phase I
Contact the Duke Recruitment Innovation Center